The Association Between Statin Drugs and Rhabdomyolysis: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles
Genes · 21.02.2025 · 16 (3) · 248
DOI: 10.3390/genes16030248 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, online erschienen am 21.02.2025. Verfasst von Robert Morris und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Science, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33613, USA. Hauptthemen laut MEDLINE: Rhabdomyolysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Adverse Drug Reaction Reporting Systems, Transcriptome. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Rhabdomyolysis, a dangerous breakdown of skeletal muscle, has been reported as an adverse event in those prescribed a statin therapy for the treatment of hypercholesterolemia. Statin drugs are some of the most prescribed treatments for elevated cholesterol levels. The purpose of this comparative study was to determine the association between the statin drugs used and the risk of rhabdomyolysis using the FDA Adverse Event Reporting System (FAERS) and transcriptomic data.
Methods
A disproportionality analysis was performed to compare the risk of rhabdomyolysis between the reference statin drug (simvastatin) and the treatment group, with patient age assessed as a possible confounder. In addition, association rule mining was utilized to both identify other adverse events that frequently presented with rhabdomyolysis and identify possible drug-drug interactions (DDIs). Finally, public transcriptomic data were explored to identify the possible genetic underpinnings highlighting these differences in rhabdomyolysis risk across statins.
Results
Rhabdomyolysis is a commonly reported adverse event for patients treated with statins, particularly those prescribed simvastatin. Simvastatin was associated with a more than 2-fold increased likelihood of rhabdomyolysis compared to other statins. Men were twice as likely to report rhabdomyolysis than women regardless of statin treatment, with the highest risk observed for pravastatin (ROR = 2.30, p < 0.001) and atorvastatin (ROR = 2.03, p < 0.0001). Several possible DDIs were identified, including furosemide/Lasix, allopurinol clopidogrel/Plavix, and pantoprazole, which may elevate rhabdomyolysis risk through impaired muscle function and delayed statin metabolism. Finally, nine myopathic genes were identified as possible regulators of statin-induced rhabdomyolysis, including DYSF, DES, PLEC, CAPN3, SCN4A, TNNT1, SDHA, MYH7, and PYGM in primary human muscle cells.
Conclusions
Simvastatin was associated with the highest risk of rhabdomyolysis. The risk of rhabdomyolysis was more pronounced in men than women. Several possible DDIs were identified including furosemide/Lasix, allopurinol clopidogrel/Plavix, and pantoprazole.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Science, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33613, USA.
- Department of Mathematics & Statistics, College of Art and Science, University of South Florida, Tampa, FL 33620, USA.
ORCID-Profile: Kun Bu, Weiru Han, Feng Cheng
Zitieren
APA
Morris, R., Bu, K., Han, W., Wood, S., Hernandez Velez, P. M., Ward, J., Crescitelli, A., Martin, M., & Cheng, F. (2025). The Association Between Statin Drugs and Rhabdomyolysis: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles. Genes, 16(3), 248. https://doi.org/10.3390/genes16030248
Vancouver
Morris R, Bu K, Han W, Wood S, Hernandez Velez PM, Ward J, et al. The Association Between Statin Drugs and Rhabdomyolysis: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles. Genes. 2025;16(3):248. doi:10.3390/genes16030248
BibTeX
@article{Morris2025,
author = {Morris, Robert and Bu, Kun and Han, Weiru and Wood, Savanah and Hernandez Velez, Paola M and Ward, Jacob and Crescitelli, Ariana and Martin, Madison and Cheng, Feng},
title = {The Association Between Statin Drugs and Rhabdomyolysis: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles},
journal = {Genes},
year = {2025},
volume = {16},
number = {3},
pages = {248},
doi = {10.3390/genes16030248}
}
EUVIMED